Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SLC1A2 | P43004 | 4/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 4/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.36 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.36 |
| ▸ | AKR1A1 | P14550 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | HTR2A | P28223 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | HRH1 | P35367 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.36 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12582817 | 1.00 | HCAR2 (0.42) | HCAR2LMNASLC1A2SLC1A1SLC1A3 | |
| SCHEMBL6343232 | 0.88 | HCAR2 (0.41) | HCAR2LMNAALDH1A1CHRM1TDP1 | |
| SCHEMBL19990339 | 0.87 | ALDH1A1 (0.50) | HCAR2LMNASLC1A2SLC1A1SLC1A3 | |
| Butane SCHEMBL9130076 | 0.86 | HCAR2 (0.40) | HCAR2LMNAALDH1A1CHRM1TDP1 | |
| SCHEMBL8613349 | 0.85 | NAAA (0.48) | HCAR2SLC1A2SLC1A1ALDH1A1GRIK1 | |
| SCHEMBL28219320 | 0.82 | ALDH1A1 (0.38) | HCAR2LMNAALDH1A1CHRM1TDP1 | |
| SCHEMBL15083214 | 0.81 | ALOX15 (0.46) | HCAR2LMNASLC1A2SLC1A1SLC1A3 | |
| SCHEMBL4405650 | 0.81 | ALOX15 (0.46) | HCAR2LMNASLC1A2SLC1A1SLC1A3 | |
| SCHEMBL12582818 | 0.81 | ALOX15 (0.46) | HCAR2LMNASLC1A2SLC1A1SLC1A3 | |
| SCHEMBL11878447 | 0.80 | CA1 (0.39) | HCAR2LMNAALDH1A1CHRM1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6946554-B2 | Process for the preparation of 9-deazaguanine derivatives | BIOCRYST PHARMACEUTICALS, INC. (US) | 2005-09-20 | — | — | US | disclosed |
| US-20040254181-A1 | Process for the preparation of 9-deazaguanine derivatives | BIOCRYST PHARMACEUTICALS, INC. | 2004-12-16 | — | — | US | disclosed |
| EP-0970029-A1 | PROCESS FOR THE PREPARATION OF 9-DEAZAGUANINE DERIVATIVES | BIOCRYST PHARMACEUTICALS INC. (US) | 2000-01-12 | — | — | EP | disclosed |
| US-5650511-A | MULTISTAGE REACTION OF ALDEHYDE OR KETONE WITH NITRILE GROUP TO FORM ENAMINE, REACTION OF ENAMINE WITH BASE TO FORM PYRROLE, THEN REACTION | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-07-22 | — | — | US | disclosed |
| WO-1997021653-A1 | PROCESS FOR THE PREPARATION OF 9-DEAZAGUANINE DERIVATIVES | BIOCRYST PHARMACEUTICALS, INC. (US) | 1997-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040254181-A1 | Process for the preparation of 9-deazaguanine derivatives | ALKBH3, ALKBH2, ALKBH1 | HCAR2 2396/4885LMNA 890/4885SLC1A2 2576/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.